Xuantai Medicine (688247.SH): The new specification of Sitagliptin and Metformin Sustained Release Tablets has been approved.

Zhtng Cijng APP News, Xuantai Pharmaceuticals (688247.SH) announced that its wholly-owned subsidiary, Jiangsu Xuantai Pharmaceuticals Co., Ltd., has received the "Drug Supplementary Application Approval Notice" issued by the National Medical Products Administration. The supplementary application for the addition of "each tablet containing 50mg of sitagliptin phosphate and 500mg of metformin hydrochloride" in the extended-release tablet of sitagliptin and metformin has been approved by the National Medical Products Administration. The extended-release tablet of sitagliptin and metformin is suitable for adult type 2 diabetes patients who are undergoing combined treatment with sitagliptin and extended-release metformin tablets.